Medicus Pharma advances pipeline during Q2 with key milestones
Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026.
The company said it received FDA "Study May Proceed" authorization for its registrational SkinJect study in patients with Gorlin Syndrome.
Its Teverelix program received Institutional Review Board authorization and positive FDA feedback for an optimized Phase 2 study in acute urinary retention, while the company also received UAE Department of Health authorization to begin the PRECISION-E2 Phase 2 study evaluating Teverelix in women with symptomatic endometriosis.
"The second quarter of 2026 marked a defining period for Medicus as we successfully advanced both of our lead therapeutic platforms into their next stages of clinical and regulatory development, while strengthening our balance sheet and financial flexibility," Medicus CEO Dr. Raza Bokhari said.
"We believe Medicus is well positioned with two differentiated programs advancing towards late-stage development, each addressing significant commercial opportunities through distinct regulatory pathways and multiple anticipated value-creating milestones."
For SkinJect, Medicus reported additional pre-specified analyses from its completed Phase 2 SKNJCT-003 study, showing clinical and histological clearance rates of 64% and 55%, respectively, at the 200 microgram dose. The company said the FDA authorization allows it to initiate the registrational SKNJCT-005 study in Gorlin Syndrome and that it continued working with the Gorlin Syndrome Alliance and clinical investigators on the development program.
The company said the developments support its planned FDA 505(b)(2) regulatory strategy for SkinJect.
For Teverelix, Medicus said it received IRB authorization and positive FDA feedback for an optimized Phase 2 study focused on preventing relapse of acute urinary retention. The company also received UAE authorization for the PRECISION-E2 study, which will use genomics to evaluate Teverelix in women with symptomatic endometriosis.
Medicus also appointed Dr. Faisal Mehmud, CEO of its Antev Limited subsidiary, as an additional role alongside his position as the company's chief medical officer.
Financially, Medicus reported cash, cash equivalents and restricted cash of $25.2 million as of June 30, including $15.2 million in cash and cash equivalents, compared with $9.7 million a year earlier.
Operating expenses rose to $11.5 million in the second quarter from $6 million a year earlier. General and administrative expenses increased to $6.6 million from $4.6 million, while research and development expenses rose to $4.9 million from $1.4 million.
The company reported a net loss of $11.7 million, or $0.21 per share, compared with a net loss of $6.2 million, or $0.43 per share, in the second quarter of 2025.
Medicus said it strengthened its financial position during the quarter through its expanded at-the-market equity program and a new secured financing facility. However, the company disclosed that substantial doubt exists regarding its ability to continue as a going concern without additional financing.
Looking ahead, Medicus said it expects to continue advancing both therapeutic platforms, with clinical and regulatory milestones and strategic partnering discussions anticipated across the programs. The company also said it expects potential expansion of strategic collaborations and licensing discussions, particularly around SkinJect, alongside further financing initiatives to support its clinical pipeline.
Shares of Medicus were up over 3% on Thursday morning.